Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Manal F. Abdelmalek"'
Autor:
Manal F. Abdelmalek, Jeongeun Hyun, Steven R. Patierno, Rebecca Caffrey, Cynthia A. Moylan, Muthana Al Abo, Anna Mae Diehl, Xiyou Zhou, Seh-Hoon Oh, Arun J. Sanyal, Kun Xiang, Rajesh Kumar Dutta, Raquel Maeso-Díaz, Jennifer A. Freedman
Publikováno v:
J Hepatol
Background & Aims Non-alcoholic fatty liver disease (NAFLD), the hepatic correlate of the metabolic syndrome, is a major risk factor for hepatobiliary cancer (HBC). Although chronic inflammation is thought to be the root cause of all these diseases,
Autor:
De Lisa Fairweather, Sanda Win, Stefano Ballestri, Tin Aung Than, Amedeo Lonardo, Fabio Nascimbeni, Ayako Suzuki, Manal F. Abdelmalek
Publikováno v:
Hepatology
Despite tremendous research advancements in nonalcoholic fatty liver disease (NAFLD), our understanding of sex differences in NAFLD remains insufficient. This review summarizes the current knowledge on sex differences in NAFLD, identifies gaps, and d
Autor:
Anna Mae Diehl, Oliver Glass, Elizabeth Bechard, Jane F. Pendergast, Cynthia D. Guy, Daniel Liu, Manal F. Abdelmalek
Publikováno v:
Hepatology Communications
Hepatology Communications, Vol 6, Iss 2, Pp 334-344 (2022)
Hepatology Communications, Vol 6, Iss 2, Pp 334-344 (2022)
Exercise is a foundational treatment for nonalcoholic fatty liver disease (NAFLD); however, the majority of patients are unable to initiate and maintain effective exercise habits and remain at increased risk for progressive liver disease. Barriers an
Autor:
Robert H. Eckel, Leon A. Adams, Christos S. Mantzoros, Kenneth Cusi, Stephen A. Harrison, Fasiha Kanwal, Eugene E. Wright, Vincent Wai-Sun Wong, Hashem B. El-Serag, Rohit Loomba, Elisabetta Bugianesi, Manal F. Abdelmalek, Lee M. Kaplan, Kim Pfotenhauer, Jay H. Shubrook
Publikováno v:
Gastroenterology, vol 161, iss 5
Gastroenterology
Gastroenterology
Find AGA's NASH Clinical Care Pathway Appfor iOS and Android mobile devices at nash.gastro.org. Scan this QR code to be taken directly to the website.Nonalcoholic fatty liver disease (NAFLD) is becoming increasingly common, currently affecting approx
Autor:
Manal F. Abdelmalek, Keri A. Seymour
Publikováno v:
Current opinion in gastroenterology. 37(3)
Purpose of review Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in the United States and increasing globally. The progressive form of NAFLD, nonalcoholic steatohepatitis (NASH), can lead to cirrhosis and compl
Autor:
Cynthia D. Guy, Ying Wang, Anna Mae Diehl, Dana Portenier, Dawn Piercy, Matthew J Crowley, Andrea D. Coviello, Anastasia-Stefania Alexopoulos, Ranjan Sudan, Cynthia A. Moylan, Manal F. Abdelmalek, Keri A. Seymour, Ricardo Henao
Publikováno v:
Hepatology (Baltimore, Md.). 74(3)
BACKGROUND AND AIMS Whether glycemic control, as opposed to diabetes status, is associated with the severity of NAFLD is open for study. We aimed to evaluate whether degree of glycemic control in the years preceding liver biopsy predicts the histolog
Autor:
Tinsay A, Woreta, Mark L, Van Natta, Mariana, Lazo, Arunkumar, Krishnan, Brent A, Neuschwander-Tetri, Rohit, Loomba, Anna, Mae Diehl, Manal F, Abdelmalek, Naga, Chalasani, Samer, Gawrieh, Srinivasan, Dasarathy, Raj, Vuppalanchi, Mohammad S, Siddiqui, Kris V, Kowdley, Arthur, McCullough, Norah A, Terrault, Cynthia, Behling, David E, Kleiner, Mark, Fishbein, Paula, Hertel, Laura A, Wilson, Emily P, Mitchell, Laura A, Miriel, Jeanne M, Clark, James, Tonascia, Arun J, Sanyal
Publikováno v:
PLOS ONE. 17:e0266859
Background and aims Management of patients with NASH who are at elevated risk of progressing to complications of cirrhosis (at-risk NASH) would be enhanced by an accurate, noninvasive diagnostic test. The new FAST™ score, a combination of FibroScan
Autor:
Sarah E. Kleinstein, David Goldstein, Cynthia A. Moylan, Cynthia D. Guy, Anna Mae Diehl, Manal F. Abdelmalek, Matthew Rein
Publikováno v:
Hepatology Communications
Hepatology Communications, Vol 2, Iss 9, Pp 1021-1029 (2018)
Hepatology Communications, Vol 2, Iss 9, Pp 1021-1029 (2018)
Nonalcoholic fatty liver disease (NAFLD) is a heterogeneous disease with highly variable outcomes. Patients with simple steatosis typically experience a benign course, whereas those with more advanced liver injury, nonalcoholic steatohepatitis (NASH)
Autor:
Atsushi Nakajima, Arun J. Sanyal, Johanna R Mora, Brent A. Neuschwander-Tetri, Edgar D. Charles, Rohit Loomba, Stephen A. Harrison, Giridhar S. Tirucherai, Diane E. Shevell, Shuyan Du, Zachary Goodman, George H. Klinger, Masayuki Yamaguchi, Richard A. Ehman, Morten A. Karsdal, Manal F. Abdelmalek
Publikováno v:
Contemporary clinical trials. 104
Background Nonalcoholic steatohepatitis (NASH) is the progressive form of nonalcoholic fatty liver disease (NAFLD); no approved therapies for NASH currently exist. Pegbelfermin (PGBF), a human fibroblast growth factor 21 analog, has metabolic effects
Autor:
Paul Y. Kwo, David I. Bernstein, Zobair M. Younossi, Ziad Younes, Mazen Noureddin, Manal F. Abdelmalek, Mark W. Russo, Mitchell L. Shiffman
Publikováno v:
The American journal of gastroenterology. 116(2)
Nonalcoholic fatty liver disease (NAFLD) is generally considered a silent and potentially reversible condition. The subtype of NAFLD that can be classified as nonalcoholic steatohepatitis (NASH) can progress to advanced fibrosis and cirrhosis. Becaus